Autifony Therapeutics Ltd. has described compounds acting as modulators of voltage-gated potassium channels from the Kv3 subfamily, such as Kv3.1, Kv3.2 and/or Kv3.3, reported to be useful for the ...
Merck Sharp & Dohme LLC has patented potassium voltage-gated channel subfamily C member 1 (Kv3.1; KCNC1) activators reported to be useful for the treatment of neurological and psychiatric disorders.
Topline Data from XEN1101 Phase 2b X-TOLE Clinical Trial in Adult Focal Epilepsy on Track for Third Quarter of 2021 BURNABY, British Columbia, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals ...
Variants of the KCNC1 gene impact K v 3.1 potassium channel function, resulting in neurodevelopmental disorders which can include progressive myoclonic epilepsy (PME) and developmental epileptic ...
CAMBRIDGE, England & TORONTO, Canada--(BUSINESS WIRE)--Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, and The KCNC1 Foundation, a not ...
A group from The Mount Sinai Hospital / Mount Sinai School of Medicine have identified and characterized a novel a GIRK1-selective activator, GiGA1 capable of selectively opening a subset of G-protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback